Rigel Pharmaceuticals (RIGL) Tops Q3 Street Views
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reports Q3 EPS of $0.96, versus the analyst estimate of $0.62. Revenue for the quarter was $72.3 million, which compares to the estimate of $55.78 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ITG (ITG) CEO Bob Gasser Replaced by Jarrett Lilien
- Trading Radar for 8/4: Zillow (Z), Archer Daniels (ADM), Hyatt Hotels (H), Kellogg (K), Sprint (S), Mosaic (MOS) Report
- Parker-Hannifin (PH) Misses Q4 EPS by 44c, FY16 Guidance Falls Short
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!